Who
Wayne Pisano
Director
Company insider
Files Form 4 as: Director, Oncolytics Biotech; Director, Altimmune; Director, Provention Bio.
In numbers
- Trades disclosed
- 36
- Buys
- 5
- Sells
- 2
- Bought
- $120K
- Sold
- $403K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 19 Jul 2018
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 1 May 2026filed 1 May 2026 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $25K30,000 at $0.8446 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $25K30,000 at $0.84 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $20K5,000 at $4.08 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ALT AltimmuneBiotechnology | SEC FORM 4 Bought | $20K5,000 at $4.08 | filing |
| 25 Sep 2025filed 29 Sep 2025 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 26 Sep 2024filed 30 Sep 2024 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,900 at $0.00 | filing |
| 28 Sep 2023filed 29 Sep 2023 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,100 at $0.00 | filing |
| 27 Apr 2023filed 27 Apr 2023 | Provention Biooption or derivative | SEC FORM 4 Code D | —128,981 | filing |
| 27 Apr 2023filed 27 Apr 2023 | Provention Biooption or derivative | SEC FORM 4 Code D | —24,000 | filing |
| 27 Apr 2023filed 27 Apr 2023 | Provention Biooption or derivative | SEC FORM 4 Code D | —22,200 | filing |
| 27 Apr 2023filed 27 Apr 2023 | Provention Biooption or derivative | SEC FORM 4 Code D | —23,000 | filing |
| 27 Apr 2023filed 27 Apr 2023 | Provention Biooption or derivative | SEC FORM 4 Code D | —33,000 | filing |
| 27 Apr 2023filed 27 Apr 2023 | Provention Bio | SEC FORM 4 Code U | —7,500 | filing |
| 22 Dec 2022filed 22 Dec 2022 | ALT Altimmuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 22 Dec 2022filed 22 Dec 2022 | ALT AltimmuneBiotechnology | SEC FORM 4 Code M | $52K20,000 at $2.60 | filing |
| 22 Dec 2022filed 22 Dec 2022 | ALT AltimmuneBiotechnology | SEC FORM 4 Sold | $300K20,000 at $15.01 | filing |
News
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026ALT · manilatimes.net · 19 Oct 2026Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 9.8% – Still a Buy?ONCY · dailypolitical.com · 16 Oct 2026Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentONCY · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Wayne Pisano; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.